Related Experiment Video

Updated: May 30, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Androgen receptor molecular biology and potential targets in prostate cancer

Elizabeth M Wilson1

  • 1Laboratories for Reproductive Biology, Lineberger Comprehensive Cancer Center, and the Departments of Pediatrics, and Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA.

Therapeutic Advances in Urology
|July 27, 2011
PubMed

Insights

Melanoma antigen gene protein-A11 (MAGE-11) enhances androgen receptor (AR) signaling in prostate cancer. This AR coactivator may be a therapeutic target for advanced prostate cancer, especially during treatment resistance.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The androgen receptor (AR) is crucial in prostate cancer and a target for therapy.
  • Prostate cancer cells develop resistance to androgen deprivation therapy (ADT) by increasing AR signaling.
  • AR coactivators play a role in amplifying AR signaling during cancer progression.

Purpose of the Study:

  • To investigate the role of melanoma antigen gene protein-A11 (MAGE-11) as an AR coactivator in prostate cancer.
  • To understand MAGE-11's function in AR stabilization and transcriptional activity, particularly under low androgen conditions.
  • To explore MAGE-11's potential as a therapeutic target in advanced prostate cancer.

Main Methods:

  • The study focuses on the molecular interactions between MAGE-11 and the androgen receptor.
  • Analysis of MAGE-11 gene expression and its correlation with prostate cancer progression.
  • Investigating MAGE-11's role in AR stabilization and transcriptional activity.

Main Results:

  • MAGE-11 is an AR-specific coactivator found only in primates, increasing AR transcriptional activity.
  • MAGE-11 levels rise during prostate cancer progression to castration-recurrent disease.
  • MAGE-11 stabilizes AR in low androgen conditions and acts as a transcriptional hub.

Conclusions:

  • MAGE-11 enhances AR function, suggesting a gain-of-function in primates for both normal physiology and cancer.
  • The evolutionary context of the MAGE-11 gene supports its role in AR activity.
  • MAGE-11 represents a potential therapeutic target for advanced prostate cancer.
Keywords:
MAGE-11MAGE-A11N/C interactionX chromosomeX-linked genesandrogen receptorcancer–testis antigens

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...